PARIS, March 31 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, today announced that Matthew Pando, Ph.D., and John Jaskowiak will join the Management Board on April 1st, 2008. At the same date, Philippe Rousseau will become President of the Management Board, until a new CEO is appointed.
Philippe Rousseau has served as CFO of ExonHit Therapeutics since 2002 and has been a member of its Management Board since 2004. John Jaskowiak, who joined ExonHit in 2006, was recently appointed Head of the Molecular Diagnostics and Genomic Services Unit and Matthew Pando, who joined the Company in 2002, was recently appointed as Head of the Therapeutics Unit.
Laurent Condomine, Chairman of the Supervisory Board, commented: "We are delighted to appoint John Jaskowiak and Matthew Pando to the Management Board, and to appoint Philippe Rousseau as President of the Management Board. The Company continues to advance development of its lead diagnostic test, for Alzheimer's disease, due to be launched in 2009, and of its lead therapeutic compound currently in Phase II, also for Alzheimer's. We are convinced that the combined expertise of Philippe, John and Matthew is essential to enable ExonHit to meet its objective of providing therapeutic and diagnostic solutions in chronic diseases, in an efficient and timely fashion. As previously announced, we have underway an active search for a new CEO for ExonHit Therapeutics."
He added: "The Supervisory Board wishes to take this opportunity to express its gratitude to the founders who have successfully developed many business opportunities, and brought the company to this important stage of development. The three founders of ExonHit will continue to provide their expertise though a consulting arrangement, focusing on ExonHit's collaboration with Allergan."
Philippe Rousseau stated: "People, technologies, patents and money are
the key assets to succeed in this fast evolvi
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved